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Background. The number of patients with severe Clostrid-
ium difficile-associated diarrhoea (CDAD) increases. Health 
care facilities are requested to establish rates of nosocomially 
acquired CDAD (N-CDAD) to understand the impact of control 
or prevention measures, and the burden of N-CDAD on health 
care resources. 
Objective. Aim of the single-center surveillance project was to 
establish local prevalence rates of N-CDAD in adult acute care 
medical patients.
Methods. For a period of at least one year, all diarrhoeal 
stools from inpatients of a general internal medicine ward were 
tested for Clostridium difficile toxin A. Case record files were 
retrospectively analysed and questionnaires were completed for 
patients with positive stool assays who met the case definitions.
Results and discussion. During the surveillance period, 2,610 
medical patients had been acutely hospitalized. Stools had been 
submitted to the hospital laboratory from 163 patients (6.2%) 
because of diarrhoea and were screened for Clostridium dif-
ficile cytotoxin. Complete data sets were available for analysis 
from 150 patients. Of 137 identified potential cases, 77 (56.2%) 
met the case definitions for nosocomial diarrhoea. Thirteen of 
the patients with nosocomial diarrhoea (16.9%) were detected 
positive by the Clostridium difficile toxin A assay. The overall 
prevalence of N-CDAD among inpatients was 8.7 cases/100 
diarrhoeal stools. The mean number of N-CDAD cases was 62.3 
cases/100,000 patient days and 5 cases/1,000 patient admissions. 
The mean age of N-CDAD patients was 79.4 years (range 71 to 
92). All patients were given broad-spectrum antibiotics before 
acute diarrhoea developed. Four patients died for reasons not 
directly related to N-CDAD which confirms increased disease 
severity as an important risk factor.
Conclusions. This single-center surveillance project, which 
established N-CDAD rates at frequencies currently reported 
from international surveys, is useful as benchmark and will 
help in understanding patterns and impact of N-CDAD at the 
regional level.
Introduction
Clostridium difficile-associated diarrhoea (cdad) is an 
increasing health problem throughout europe, canada, 
and the United States with mortality rates rising. an 
increasing number of patients develop this illness in the 
community, although many with cdad were recently 
discharged from a healthcare setting suggesting an acqui-
sition of infection in the hospital environment [1]. the 
use of gastric acid-altering drugs that facilitate intestinal 
transit of the bacteria, antibacterial drugs that deplete co-
lonic flora and presence of inflammatory bowel disease 
are identified risk factors for cdad [1]. although the 
majority of patients remain asymptomatic following ac-
quisition of Clostridium difficile, it is still the most com-
monly identified cause of nosocomial (n) diarrhoea [2].
cdad surveillance includes multi-centre national stud-
ies, description of periodic outbreaks or endemic situa-
tions in health care facilities, survey of elderly people, 
and study of specific wards, eg, medical and surgi-
cal [3]. however, it is useful to survey specifically n-
cdad cases, because they represent illness that may be 
prevented by hospital infection prevention and control 
practices. consequently, the nosocomial acquisition of 
Clostridium difficile may represent inadequate infection 
control practices [4]. this underscores the importance 
of instigating measures to monitor the prevalence of n-
cdad, and implementing and assessing the efficacy of 
any prevention or control practices. 
there are only few italian studies in the literature that ex-
amine the role of n-cdad infections [5-10]. therefore, 
a single-site n-cdad prevalence project was undertaken 
with the intent to contribute with the data to health care 
facility n-cdad prevalence rates that could be inserted 
in future benchmark data for other italian health care fa-
cilities, and to assist with the development and evaluation 
of guidelines that may decrease the incidence and cost of 
n-cdad within italian health care facilities. 
Methods
at the central hospital of bolzano, an 800-bed aca-
demic teaching hospital of the autonomous Province of 
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bolzano, italy, affiliated with the Medical University of 
innsbruck, austria, all inpatient stools submitted from the 
2nd division of internal Medicine (60 beds; general inter-
nal medicine with specialized units for endocrinology and 
angiology; about 2,200 patients annually; mean length 
of stay 8.0 days) to the hospital laboratory in a liquid or 
semiformed condition were analysed for the presence 
of Clostridium difficile toxin by the method currently 
in use, ie, cytotoxin a assay, and/or for bacterial stool 
culture regardless of the clinical indication for the speci-
men. a “Clostridium difficile case” was defined to be any 
person with nosocomial diarrhoea and stool containing 
Clostridium difficile cytotoxin. The patients’ charts were 
reviewed to determine whether the patient met the case 
definition of n-cdad, which was acute onset of > 3 
loose stools per day that persisted for at least 2 days [7]. 
in addition, all cdad cases had to fulfill one criterium 
to ensure that it was a case of n-cdad: the symptoms 
occurred two days or more after admission. 
data were collected between January 1, 2007 and January 
12, 2008. in addition to the results of Clostridium difficile 
toxin a testing (Vidas® c. difficile toxin a, biomérieux) 
and bacterial culture for Salmonella / Shigella and Campy-
lobacter sp., further information was collected, including 
sex, age, whether patient was on antimicrobial medications 
at the time of stool specimen collection, and details on the 
treatments of n-cdad. Primary cases were followed until 
death or discharge; relapses or re-infections of n-cdad 
were not systematically documented. The patients’ out-
come at discharge was recorded, as well as the length of 
stay or time to death. deaths directly or indirectly attrib-
uted to n-cdad were defined respectively as due to coli-
tis (eg, hemorrhage or perforation) or complications that 
would not have occurred if n-cdad had not developed 
(eg, dehydration, debilitation). laboratory information 
collected included the time period over which diarrhoeal 
stools were screened, and the total number of samples and 
patients tested. duplicate specimens were not analyzed.
Results
during the surveillance period, 2,610 inpatients had been 
hospitalized at the general medical ward. their mean 
age was 71.5 years with an overall range from 17 to 100 
years (median 75 years). Stools had been submitted to the 
hospital laboratory from 163 patients (6.2%) because of 
diarrhoea in order to screen for Clostridium difficile cyto-
toxin (duplicate samples eliminated) and for pathogenic 
bacteria Salmonella, Shigella or campylobacter (fig. 1).
from the total of 163 samples, complete data sets were 
available for 150 patients and were analysed. of 137 
potential cases, 77 (56.2%) met the case definitions for 
nosocomial diarrhoea. Sixty (43.8%) cases did not meet 
the case definition of nosocomial diarrhoea because they 
did not meet the criteria to be considered nosocomially 
acquired, the diarrhoea did not persist for at least two 
days or the diarrhoea could be explained by other caus-
es, such as chemotherapy. thirteen of the patients with 
nosocomial diarrhoea (16.9%) were detected positive by 
the Clostridium difficile toxin a assay, and three (3.9%) 
were found positive for stool pathogenic bacteria. thus, 
the overall prevalence of n-cdad among inpatients 
was 8.7 cases/100 diarrhoeal stools. the mean number 
of n-cdad cases was 62.3 cases/100,000 patient days 
and 5 cases/1,000 patient admissions.
the characteristics of the patients with n-cdad can be 
seen in table 1. Seven patients (54%) with n-cdad were 
female, while 6 (46%) were male. the mean age was 79.4 
years with an overall range from 71 to 92 years, which was 
above the hospitalized patients average age (p < 0.05). the 
mean length of time from admission to onset of symptoms 
was 7.3 days with a range of 3 days to 16 days and a median 
of 8 days. the mean (± standard deviation) length of time 
from onset of symptoms to laboratory specimen collec-
tion was 2.9 (± 1.7) days. the mean length of stay (loS) 
in hospital was 17.2 days with an overall range from 7 to 
46 days again longer than the average LOS of the ward’s 
patients. four patients (31%) died for reasons that were un-
related to n-cdad diarrhoea (two died of multiple organ 
failure due to severe sepsis of bacterial blood stream infec-
tion and pneumonia, respectively; one died of arrhythmia 
in cardiogenic shock because of decompensated chronic 
heart failure; and one of global respiratory insufficiency 
due to end-stage chronic obstructive pulmonary disease 
already on home oxygen therapy already for years); mean 
age of the patients who died was 82.2 years with an overall 
range from 79 to 84 years which was similar to the mean 
age of n-cdad patients who survived (mean 78.1 years, 
range 67 to 92 years). 
all patients with n-cdad were on antibacterial medica-
tions at the time of stool specimen collection; 4 (30.8%) 
Fig. 1. Breakdown of the results of the nosocomial Clostridium diffi-
cile-associated diarrhoea (N-CDAD) prevalence surveillance project.
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were on one antibiotic and 9 (69.2%) were on two or 
more antibiotics. five patients (38.5%) with n-cdad 
received concomitant antacid medications. Seven of 
the patients (54%) were given no antibiotics to treat n-
cdad either because of diarrhoea had ended spontane-
ously before arrival of test result, antibiotic therapy had 
been stopped and/or probiotics had been prescribed. the 
principal antibiotic used as therapy, oral metronidazole, 
was administered in 5 (38%) n-cdad cases, intrave-
nous metronidazole was administered in 1 case (8%), 
oral or intravenous vancomycin were not given.
Discussion
the prevalence of Clostridium difficile carriage in 
asymptomatic and otherwise healthy adult stool cultures 
is < 5% [11]. in contrast, the rate of carriage among 
hospitalised patients varies significantly and may be as 
high as 25% [12]. the present prevalence surveillance 
project identified 13 cases of n-cdad among a total 
of 150 diarrhoeal patients analysed, thus, yielding a 
prevalence rate of 8.7%. the rates of cdad as reported 
in the literature vary because they are based on different 
definitions of cdad. according to recent recommenda-
tions the cases described here represent healthcare facil-
ity–onset, healthcare facility–associated (ho-hcfa) 
cases of cdad [13]. a canadian, multicentre, national 
point prevalence project on n-cdad included nosoco-
mial patients who had diarrhoea for at least two days 
that could not be explained by another cause, and a 
prevalence rate of 13% had been found [3]. their selec-
tive case definition decreased the probability of false 
positives. the same case definition for n-cdad was, 
therefore, also applied in the present study that was per-
formed in adult patients from a medical ward. thus, the 
observed prevalence rate of 8.7% is in the range of rates 
that was previously reported for medical ward patients 
which are known to have the highest frequencies of n-
cdad among the various health care facilities [3].
cdad is reportedly more common among older indi-
viduals [14]. age 50-80 years and age > 80 years were 
significantly associated with disease, and haemodi-
alysis, non-surgical admission and increasing length of 
stay in the intensive care unit also being listed as risk 
factors [15]. In the current study, patients’ age ranged 
from 67 to 92 years, among them 5 patients being 81 
years or older. all patients were non-surgical. haemo-
dialysis and intensive care unit stay were not risk factors 
here due to the particular case mix of the medical ward 
under study.
in addition to increased severity of illness and increased 
age, prior antimicrobial use, particularly use of clindamy-
cin, cephalosporins, and, more recently, fluoroquinolones 
and gastric acid suppressors are identified and proposed 
risk factors of cdad, respectively [15, 16]. not surpris-
ingly, all patients with n-cdad of the current survey 
had received antibiotic treatment at the time of stool 
specimen collection. however, the majority of patients 
with n-cdad (61.5%) have not received antacid medi-
cations concomitantly. this observation might be inter-
preted in light of an ongoing controversy regarding the 
role of proton pump inhibitor treatment as a risk factor 
for cdad [16, 17].
the morbidity and mortality associated with cdad 
infections can be significant [18]. in the present project, 
four (30.8%) of the patients with n-cdad died because 
of co-morbidities and complications unrelated to cdad. 
this mortality rate reflects the particular case mix of the 
general medical ward under study with a high rate of 
acute medical illnesses and a median patient age above 
70 years but not complications of cdad. Mortality at-
tributed to cdad is much lower. thus, in a 10-year sur-
veillance project at one centre in the United States five 
of the 9,008 (0.6%) cdad cases had identified cdad 
as the primary cause of death [19]. Similarly, low mor-
tality rates have been found in a canadian surveillance 
project in 2001 of 1.5% [3]. Most likely, elevated dis-
ease severity which leads to increased mortality has also 
been a relevant risk factor for developing n-cdad. it 
cannot be excluded, however, that, in our study, cdad 
indirectly contributed to patient mortality. 
as before, our acute medical health care facility did not 
know whether rates of N-CDAD were ‘high’ or ‘low’, 
the perception of whether n-cdad is a problem does 
not appear to correspond with the observed rates of 
n-cdad, according to nosocomial infection surveil-
lance projects [3]. not understanding what should be 
Tab. I. Characteristics of patients of acute care nosocomial Clostridium difficile-associated diarrhoea (N-CDAD) participating in the 2007 
retrospective surveillance program of a general medicine ward of the Central Hospital of Bolzano, Italy (n = 13).
Characteristic Value
Mean age 79.4 years
(Range from 71 to 92 years)
Sex
   Male
   Female
6 (46%)
7 (54%)
Length of time from admission to acute onset of N-CDAD symptoms Mean 7.3 days
Median 8 days
Average length of stay (surviving cases) Mean 17.2 days
Median 16 days
Number of patients with N-CDAD receiving antibacterial medications at the 
time of stool specimen collection
13 (100%)
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acceptable rates of cdad requires good benchmark 
data for comparisons and education. a recent Medi-
terranean survey from the Medical School of bursa, 
turkey, reported an incidence of nosocomial diarrhoea 
of 60 per 100,000 hospitalization-days and 5 per 1,000 
patients’ admissions; the incidence of N-CDAD was 
26 per 100,000 hospitalization-days and 2.1 per 1,000 
admissions [20]. a recent surveillance study includ-
ing eight european countries and 112 laboratories 
reported the incidence of n-cdad to be 1.1 case per 
1,000 admissions [21]. this incidence is lower than 
those reported in north america [3]. the european 
study was a questionnaire-based survey including the 
laboratory of bacteriology, istituto Superiore di San-
ità, Rome, that suggest marked discrepancies between 
laboratories and also between countries regarding the 
criteria by which C. difficile is investigated for, and the 
methods and the strategies that are used for the diag-
nosis of C. difficile [21]. More than 90 percent of the 
participating european laboratories reported that they 
assay directly for C. difficile toxins in the stools, and 
among them an overall of 58 percent detect only toxin 
a [21], which was the case also in our study. however, 
literature on nosocomial diarrhoea is still difficult to 
compare also because of different definitions, different 
hygienic measures being used for patients with diar-
rhoea, and the presence of epidemics during the study 
period [22].
the current study may help to build up italian bench-
mark rates that should assist hospital administration in 
decision making regarding the necessary infection con-
trol measures within their institutions.
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